Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
SAN DIEGO, Calif., Oct. 26, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to release its third quarter 2017 financial results before the market opens on Friday, November 3, 2017. The company will hold a conference call and simultaneous webcast at 8:30 AM, Eastern Time (5:30 AM Pacific Time) on Friday, November 3, 2017 to discuss the company's financial results and provide a business update. Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 5996758. Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event. The conference call will also be webcast live at: http://edge.media-server.com/m6/p/5238gynk
A replay of the call will be available through November 10, 2017, 10:30 am EST by calling (855) 859-2056 (U.S.) or (404) 537-3406 (international), using passcode 5596758. An archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics website located at http://investor.obalon.com in the “News & Events” section.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc.
Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
[email protected]
Media:
Megan Driscoll
EvolveMKD
Office Phone: +1 646 517 4220
[email protected]
